Christopher V.. Chambers, MD
Philadelphia, PA 19107
Most Recent Peer-reviewed Publications
- Effective Strategies to Improve the Management of Heart Failure
- Cancer Vaccines
- Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: A randomized study in US adults
- Screening and Prevention: Cervical Cancer
- Hematuria: etiology and evaluation for the primary care physician.
A.B. Princeton University - 1976
M.D. Duke University School of Medicine - 1980
Residency, Family Medicine, Thomas Jefferson University Hospital - 1983
Fellowship, Adolescent Medicine, University of California, San Francisco - 1985
Board Certified, Family Medicine
Board Certified, Adolescent Medicine
Professor and Director, Clinical Trials
Family and Community Medicine
Thomas Jefferson University
Research and Clinical Interests
Over the past 10 years, I have been Principal Investigator for more than 10 clinical trials involving vaccines, primarily the HPV (human papilloma virus) vaccine. These phase II and phase III trials have been safety and efficacy studies in various populations including adolescent and young adult women, ages 15-25; older women, ages 26-45; MSMs (men who have sex with men); as well as immunologic studies of the HPV vaccine given in various combinations with other immunizations in adolescents and a head to head trial of the GSK HPV vaccine and the Merck HPV vaccine. In the international pivotal trial of the GSK vaccine, our site was the second highest enroller in the world. In the study of MSMs, we were the third leading enroller.
In addition to our HPV studies, we have also completed a clinical and immunological study of two FDA-approved influenza vaccines. In 2008, we are scheduled to participate in a study of the pertussis vaccine in the elderly and another influenza vaccine study.
My clinical department has nearly 80,000 outpatient visits per year. The department also has several clinical satellite offices and its faculty staffs the Philadelphia Senior Center, which serves another 7,000 clients. The chair of my department, Richard Wender, MD, has helped me build the infrastructure to attract and complete vaccine trials which are consistent with the department’s clinical and research commitment to prevention and chronic disease management.